Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 19/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 1.00 |
| ▸ | MMP3 | P08254 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988421 | 1.00 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL29518647 | 1.00 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4012395 | 0.96 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4012390 | 0.96 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4012924 | 0.96 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4012732 | 0.95 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4012410 | 0.95 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4013067 | 0.95 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4010137 | 0.92 | MMP12 (0.93) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL4011080 | 0.91 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074107-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | claimed |
| EP-4334354-A1 | ANTIBODIES AGAINST ALK AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-106661008-A | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases | 拜耳制药股份公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170119776-A1 | CHIRAL 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170114049-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| EP-3126339-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-3126358-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATOY TRACT DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-3126340-A2 | CHIRAL 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022171-A1 | 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACIDS AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015189117-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015150363-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150350-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATOY TRACT DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150366-A1 | CYCLICALLY SUBSTITUTED PHENOL ETHER DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150362-A2 | CHIRAL 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150364-A1 | SUBSTITUTED BENZOTRIAZINONE BUTANE ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-08 | — | — | WO | disclosed |
| EP-2074107-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114049-A1 | 2,5-DISUBSTITUTED CYCLOPENTANE CARBOXYLIC ACIDS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | CA5A, PC, CA5B | MMP12 1555/4885MMP13 1867/4885MMP2 2719/4885 |
| US-20170022171-A1 | 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACIDS AND THEIR USE | PC, PYCR1, PCCA | MMP12 1492/4885MMP13 1742/4885MMP2 2762/4885 |
| US-20170119776-A1 | CHIRAL 2,5-DISUBSTITUTED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND USE THEREOF | FABP3, CYP11B2, HCAR2 | MMP12 1595/4885MMP13 1877/4885MMP2 3275/4885 |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | ABAT, HADHB, CYP11B2 | MMP12 3200/4885MMP13 3030/4885MMP2 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.